Etcamah (camizestrant)

Where it stands

Etcamah (camizestrant), from AstraZeneca, is approved in both the US and the EU. The FDA approved it on 2026-09-04 as a new medicine, under NDA220359, in tablet form. In the EU, the European Commission granted a marketing authorisation to AstraZeneca AB on 2026-07-20, after a positive CHMP opinion on 2026-05-21.

The EU approval came about 46 days before the US approval. The records give no information on the therapeutic area or the approved indication, so this analysis cannot say which patients the product is authorised to treat in either region. The summary line shows no CHMP opinion date, but the milestone list records the opinion on 2026-05-21. I have used the milestone date.

Regulatory pathway and designations

In the US, the product was reviewed as a new molecular entity under a New Drug Application. That means the active substance had not previously been approved by the FDA. The records list no other designations, such as priority review, breakthrough therapy, fast track or orphan status. They do not show whether any were granted, and nothing should be inferred either way.

In the EU, the sequence is the standard one for a centrally authorised product. The CHMP adopted a positive opinion on 2026-05-21, and the Commission's decision followed on 2026-07-20, roughly two months later. The Commission usually takes about that long to convert an opinion into a legally binding authorisation valid across the EU. The EU product is also named Etcamah and has the status 'Authorised'.

Safety and pharmacovigilance

The EU authorisation carries 'additional monitoring' status. Products with this status are listed with a black inverted triangle in the product information, and healthcare professionals and patients are encouraged to report any suspected adverse reactions. The status is applied, for example, to new active substances. It does not in itself indicate a specific safety concern.

The records contain no safety data. They give no warnings, contraindications, boxed warning, REMS, risk management plan details or post-marketing commitments for the US or the EU. They do not describe the US label. A safety assessment would need the approved prescribing information and the EU product information.

What to watch

The first priority is to obtain the US prescribing information and the EU product information. These will set out the approved indication, dosing, warnings and any post-approval requirements, none of which appear in the records. Comparing the two texts will show whether the US and EU labels differ in scope.

Further regulatory activity may follow, such as launch-related updates, label changes or additional-monitoring reporting. The records give no dates or details for any of these, so none can be forecast here.